Wednesday, July 12, 2006

Johnson and Johnson Trojan Horse

Johnson and Johnson (NYSE:JNJ) is touting results from a new drug dealing with Schizophrenia. Phase III results have been presented to a scientific body and press released. The pressure is on regulators to approve. No comment about any regulatory concerns or issues. It sounds like clear sailing. Will lawsuits come latter?